Related ArticlesA Parkinson's disease CircRNAs Resource reveals a link between circSLC8A1 and oxidative stress. EMBO Mol Med. 2020 Nov 06;12(11):e13551 Authors: Hanan M, Simchovitz A, Yayon N, Vaknine S, Cohen-Fultheim R, Karmon M, Madrer N, Rohrlich TM, Maman M, Bennett ER, Greenberg DS, Meshorer E, Levanon EY, Soreq H, Kadener S PMID: 33438831 [PubMed] ... read more
Source: PubMedPublished on 2021-01-14
Related Articles:
- Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
- Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
- Monthly Research Review – November 2020 November 30, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- NEAT1 is overexpressed in Parkinson's disease substantia nigra and confers drug-inducible neuroprotection from oxidative stress. July 18, 2019 NEAT1 is overexpressed in Parkinson's disease substantia nigra and confers drug-inducible neuroprotection from oxidative stress. FASEB J. 2019 Jul 16;:fj201900830R Authors: Simchovitz A, Hanan M, Niederhoffer N, Madrer N, Yayon N, Bennett ER, Greenberg DS, Kadener S, Soreq H Abstract Recent reports attribute numerous regulatory functions to the nuclear paraspeckle-forming long noncoding RNA, nuclear enriched assembly transcript 1 (NEAT1), but…
- Journey with Parkinson’s: (Part 1) Another Side of Life October 27, 2020 “All we have to decide is what to do with the time that is given us.” J. R. R. Tolkien “We must not allow the clock and the calendar to blind us to the fact that each moment of life is a miracle and mystery.” H. G. Wells Introduction: Parkinson’s changes us in many ways: it makes us stronger by…
- Journey with Parkinson’s: (Part 1) Another Side of Life October 27, 2020 “All we have to decide is what to do with the time that is given us.” J. R. R. Tolkien “We must not allow the clock and the calendar to blind us to the fact that each moment of life is a miracle and mystery.” H. G. Wells Introduction: Parkinson’s changes us in many ways: it makes us stronger by…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Life with Parkinson’s in the Time of COVID-19: April is Parkinson’s Awareness Month April 1, 2020 “The measure of who we are is what we do with what we have.” Vince Lombardi “When you have exhausted all possibilities, remember this: you haven’t.” Thomas Edison Précis: A different world exists today than it did just a few weeks ago, all driven by the COVID-19 pandemic. The virus seemingly favors the elderly who have a pre-existing disease(s); however,…
- Life with Parkinson’s in the Time of COVID-19: April is Parkinson’s Awareness Month April 1, 2020 “The measure of who we are is what we do with what we have.” Vince Lombardi “When you have exhausted all possibilities, remember this: you haven’t.” Thomas Edison Précis: A different world exists today than it did just a few weeks ago, all driven by the COVID-19 pandemic. The virus seemingly favors the elderly who have a pre-existing disease(s); however,…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Monthly Research Review: Jaunary 2020 January 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
- Am I being unreasonable? November 16, 2018 Friday 16 November 2018If you’re feeling a bit down and need a quick pick-me-up, you could do worse than browse the discussion threads on mumsnet for a while.I’m not talking about the posts on pregnancy or breast feeding or dealing with toddlers. I’m talking about the “other” section. The most popular category on mumsnet is AIBU, for Am I Being…
- ALS: From ice bucket to centaur November 18, 2020 # # # # Amyotrophic lateral sclerosis (or ALS) is the third most common neurodegenerative condition. It is characterised by the loss of motor neurons, which leads to loss of muscle control. As with Parkinson’s, there is no cure for ALS, and there are only two FDA approved therapies for the condition. Recently, a biotech company – called Amylyx Pharmaceuticals…
- A plutocratic proposal: iCancer February 2, 2020 Speeding up the clinical development process is a shared goal across many medical conditions (not just Parkinson’s and neurodegeneration), and there are many different approaches to achieving this that are being explored. Some of these approaches could be considered to be bordering on the unethical, but there are aspects of their structure and design that are still worthy of…
- Yo DJ, stop mis-splicing November 16, 2020 # # # # RNA – the usable copy of a section of DNA – has regions called introns that need to be removed before the RNA can be used for the production of protein. The process of removing introns is called splicing. Recently researchers have noticed that a genetic mutation in a Parkinson’s-associated gene – called DJ-1 – affects…
- The drug development pipeline for Parkinson’s December 2, 2020 # # # # For a long time a regular request from SoPD readers has been to provide an overview of the clinical trial landscape for Parkinson’s, particularly in the area of drug development. Such projects are difficult, however, as the landscape is broad and dynamic – lots of different approaches being applied and new entrants continually entering the arena.…
- Very Keynesian: Cell painting November 25, 2020 # # # # Our ability to grow cells in culture (in petri dishes and flasks in laboratories) has been critical to our efforts to learn more about the biology of Parkinson’s and to screen for novel potential therapies. Recently, researchers have employed more sophisticated methods of characterising cells in culture, to achieve greater insights. These effort have led to…
- PARP-kinson’s goes chlorogenic December 20, 2020 # # # # For a long time it was been reported that coffee may be able to reduce the risk of developing Parkinson’s, but the mechansim by which this association could be occurring has remained elusive. Now researchers from South Korea have discovered a biological pathway that could help to explain the protective association. It involves a protein called…
- TGF-beta: The Parkinson’s superfamily? December 12, 2020 # # # # A lot of Parkinson’s research has focused on a neurotrophic factor called glial cell-derived neurotrophic factor (or GDNF). But GDNF only represents a small fraction of a much larger class of neurotrophic factors, called the Transforming growth factor-β (TGF-β) superfamily. Recently, researchers have been investigating some of the other TGF-β family members in preclinical models of…
- The Wim Hof method February 6, 2020 A regular theme of the SoPD website is the reviewing of novel phamarcological treatments that are being tested on models of Parkinson’s. And while the breadth of the research is exciting and encouraging, the average reader may feel distant to the results of those studies as the experimental drug being tested is still a long way from possible regulatory…